GLP-1 Drugs Like Ozempic Linked to 30% Lower Breast Cancer Risk in Major Study
A study of 110,000+ women found GLP-1 users had ~30% lower breast cancer risk, sparking plans for clinical trials.
20 articles
A study of 110,000+ women found GLP-1 users had ~30% lower breast cancer risk, sparking plans for clinical trials.
New trial data reveals AstraZeneca's experimental in vivo CAR-T therapy showed early responses in multiple myeloma patients but resulted in one death.
New study shows PCSK9 inhibitor prevents cardiovascular events in high-risk diabetes patients without existing heart disease.
Breakthrough non-invasive device offers new hope for pancreatic cancer patients with at-home treatment option.
A once-undruggable cancer driver has finally been targeted, cutting death risk by 60% in a landmark 500-patient trial.
Redesigned immunotherapy injected into one tumor triggered complete cancer remission in 2 of 12 patients, with untreated tumors also disappearing.
A newly identified molecule called SLAMF6 exhausts cancer-fighting T cells from within โ and blocking it may revive failed immunotherapies.
A short pre-surgery course of pembrolizumab left zero relapses in colorectal cancer patients after 33 months โ reshaping treatment strategy.
Breakthrough blood test combining four biomarkers catches deadly pancreatic cancer early when treatment works best, detecting 87.5% of stage I/II cases.
New study finds 27% of patients with treatment-resistant hypertension have elevated cortisol levels that could explain medication failures.
New research reveals why BET inhibitor cancer drugs work in labs but fail in patients, pointing to better treatment strategies.
Australian biotech company creates targeted treatment that attacks malignant plasma cells while sparing healthy ones in multiple myeloma patients.
Bemnifosbuvir blocks hepatitis E replication in lab tests, offering hope for treating a virus that kills 70,000 people annually.
Scientists discover D-cysteine selectively targets cancer cells by disrupting their energy production without harming normal cells.
Disabling the NFIL3 protein prevents CAR T cell exhaustion, boosting tumor-fighting power in animal models of hard-to-treat cancers.
Single injection of engineered virus kills glioblastoma cells and activates immune system, extending patient survival in clinical trial.
A landmark study of 500 cat tumors reveals shared cancer-driving mutations with humans, pointing toward new breast cancer treatments.
A small molecule called UNI418 shuts down cancer cells' DNA repair machinery, making drug-resistant tumors vulnerable to treatment again.
Scientists discover why identical cancer treatments work for some patients but fail for others, revealing hidden drug reservoirs in cells.
New research reveals how tumors communicate with immune cells to avoid detection, potentially leading to better biomarkers and treatments.